메뉴 건너뛰기




Volumn 64, Issue 5, 2010, Pages 534-536

Transdermal rivastigmine for Alzheimer's disease: Skin deep or scratching the surface?

Author keywords

[No Author keywords available]

Indexed keywords

LIDOCAINE; RIVASTIGMINE; ROTIGOTINE;

EID: 77949404624     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02305.x     Document Type: Editorial
Times cited : (5)

References (19)
  • 1
    • 77949383588 scopus 로고    scopus 로고
    • Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer's disease
    • Grossberg GT, Sadowsky C, Olin JT. Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer's disease. Int J Clin Pract 2010; 64: 651-60.
    • (2010) Int J Clin Pract , Issue.64 , pp. 651-660
    • Grossberg, G.T.1    Sadowsky, C.2    Olin, J.T.3
  • 3
    • 0036257075 scopus 로고    scopus 로고
    • The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: An hypothesis
    • Bullock R. The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis. Int J Clin Pract 2002; 56: 206-14.
    • (2002) Int J Clin Pract , vol.56 , pp. 206-214
    • Bullock, R.1
  • 4
    • 10044283107 scopus 로고    scopus 로고
    • Rivastigmine for dementia associated with Parkinson's disease
    • Emre M, Aarsland D, Albanese A et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351: 2509-18.
    • (2004) N Engl J Med , vol.351 , pp. 2509-2518
    • Emre, M.1    Aarsland, D.2    Albanese, A.3
  • 5
    • 0034676757 scopus 로고    scopus 로고
    • Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebo-controlled international study
    • McKeith I, Del Ser T, Spano P et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356: 2031-6.
    • (2000) Lancet , vol.356 , pp. 2031-2036
    • McKeith, I.1    Del Ser, T.2    Spano, P.3
  • 6
    • 64149090366 scopus 로고    scopus 로고
    • Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: A review
    • Kurz A, Farlow M, Lefèvre G. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review. Int J Clin Pract 2009; 63: 799-805.
    • (2009) Int J Clin Pract , vol.63 , pp. 799-805
    • Kurz, A.1    Farlow, M.2    Lefèvre, G.3
  • 7
    • 36248987178 scopus 로고    scopus 로고
    • Rotigotine transdermal patch: A review of its use in the management of Parkinson's disease
    • Baldwin CM, Keating GM. Rotigotine transdermal patch: a review of its use in the management of Parkinson's disease. CNS Drugs 2007; 21: 1039-55.
    • (2007) CNS Drugs , vol.21 , pp. 1039-1055
    • Baldwin, C.M.1    Keating, G.M.2
  • 8
    • 51749085099 scopus 로고    scopus 로고
    • Rotigotine transdermal patch: In restless legs syndrome
    • Baldwin CM, Keating GM. Rotigotine transdermal patch: in restless legs syndrome. CNS Drugs 2008; 22: 797-806.
    • (2008) CNS Drugs , vol.22 , pp. 797-806
    • Baldwin, C.M.1    Keating, G.M.2
  • 9
    • 2342523953 scopus 로고    scopus 로고
    • Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia
    • Davies PS, Galer BS. Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia. Drugs 2004; 64: 937-47.
    • (2004) Drugs , vol.64 , pp. 937-947
    • Davies, P.S.1    Galer, B.S.2
  • 10
    • 34249683625 scopus 로고    scopus 로고
    • A six-month double-blind, randomized, placebo-controlled study of transdermal patch in Alzheimer's disease - rivastigmine patch versus capsule
    • Winblad B, Cummings J, Andreasen N et al. A six-month double-blind, randomized, placebo-controlled study of transdermal patch in Alzheimer's disease - rivastigmine patch versus capsule. Int J Geriatr Psychiatry 2007; 22: 456-67.
    • (2007) Int J Geriatr Psychiatry , vol.22 , pp. 456-467
    • Winblad, B.1    Cummings, J.2    Andreasen, N.3
  • 11
    • 67651071488 scopus 로고    scopus 로고
    • Safety and tolerability of the rivastigmine patch: Results of a 28-week open-label extension
    • Grossberg G, Sadowsky C, Forstl H et al. Safety and tolerability of the rivastigmine patch: results of a 28-week open-label extension. Alzheimer Dis Assoc Disord 2009; 23: 158-64.
    • (2009) Alzheimer Dis Assoc Disord , vol.23 , pp. 158-164
    • Grossberg, G.1    Sadowsky, C.2    Forstl, H.3
  • 12
    • 34249705681 scopus 로고    scopus 로고
    • Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease
    • Winblad B, Kawata AK, Beusterien KM et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. Int J Geriatr Psychiatry 2007; 22: 485-91.
    • (2007) Int J Geriatr Psychiatry , vol.22 , pp. 485-491
    • Winblad, B.1    Kawata, A.K.2    Beusterien, K.M.3
  • 13
    • 66149089567 scopus 로고    scopus 로고
    • Transdermal rivastigmine patch in outpatient services in Austria: A naturalistic study in 103 patients with Alzheimer dementia
    • in German
    • Schmidt R, Alf C, Bancher C et al. Transdermal rivastigmine patch in outpatient services in Austria: a naturalistic study in 103 patients with Alzheimer dementia [in German]. Neuropsychiatr 2009; 23: 58-63.
    • (2009) Neuropsychiatr , vol.23 , pp. 58-63
    • Schmidt, R.1    Alf, C.2    Bancher, C.3
  • 14
    • 0345276668 scopus 로고    scopus 로고
    • Strategies for continued successful treatment of Alzheimer's disease: Switching cholinesterase inhibitors
    • Gauthier S, Emre M, Farlow MR, Bullock R, Grossberg GT, Potkin SG. Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors. Curr Med Res Opin 2003; 19: 707-14.
    • (2003) Curr Med Res Opin , vol.19 , pp. 707-714
    • Gauthier, S.1    Emre, M.2    Farlow, M.R.3    Bullock, R.4    Grossberg, G.T.5    Potkin, S.G.6
  • 17
    • 78049470959 scopus 로고    scopus 로고
    • Larner AJ. Cholinesterase inhibitors: beyond Alzheimer's disease. Expert Rev Neurotherapeutics 2010; 10. in press.
    • Larner AJ. Cholinesterase inhibitors: beyond Alzheimer's disease. Expert Rev Neurotherapeutics 2010; 10. in press.
  • 18
    • 34248372938 scopus 로고    scopus 로고
    • Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: The InDDEx study
    • Feldman HH, Ferris S, Winblad B et al. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol 2007; 6: 501-12.
    • (2007) Lancet Neurol , vol.6 , pp. 501-512
    • Feldman, H.H.1    Ferris, S.2    Winblad, B.3
  • 19
    • 70349306585 scopus 로고    scopus 로고
    • Cholinesterase inhibition: Is there evidence for disease-modifying effects?
    • Shanks M, Kivipelto M, Bullock R, Lane R. Cholinesterase inhibition: is there evidence for disease-modifying effects? Curr Med Res Opin 2009; 25: 2439-46.
    • (2009) Curr Med Res Opin , vol.25 , pp. 2439-2446
    • Shanks, M.1    Kivipelto, M.2    Bullock, R.3    Lane, R.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.